About Us
Advancing Innovation. Transforming Lives.
Servier Pharmaceuticals is a Boston-based, commercial-stage biopharmaceutical company dedicated to advancing innovative treatments and improving the lives of patients facing complex and difficult-to-treat diseases.
As the U.S. subsidiary of Servier Group, the company operates under the governance of a nonprofit foundation. This unique structure allows Servier to pursue a long-term, patient-centered approach to research and innovation, free from the influence of external investors and short-term market pressures.
Established in the United States in 2018, Servier Pharmaceuticals focuses on developing and delivering innovative therapies in oncology and neurology. In oncology, the company has established a portfolio of first-in-class and best-in-class medicines, advancing precision treatments designed to address unmet medical needs and improve patient outcomes.
Building on its expertise in oncology, Servier continues to expand its presence in neurology, applying the same dedication to scientific excellence, strategic collaboration, and patient-focused innovation.
Putting Patients at the Center of Everything We Do
At Servier, patients are the driving force behind every decision, discovery, and advancement. We believe that listening to and understanding the patient experience is essential to developing meaningful therapeutic solutions.
Through scientific innovation, collaboration, and an unwavering commitment to patient care, Servier Pharmaceuticals strives to transform treatment possibilities, improve health outcomes, and make a lasting difference in the lives of patients, families, and communities worldwide.
